H.C. Wainwright analyst Edward White maintained a Buy rating on G1 Therapeutics Inc (GTHX) today and set a price target of $72. The company’s shares opened today at $23.75.
White noted:
“We believe that an OS benefit seen in a small three-arm trial like this (n=102) is an important result and believe the company can now pursue an efficacy benefit as well as the myelopreservation pathway, which we discuss below, for commercialization. We look forward to seeing the data later this year and management’s strategy for obtaining regulatory approval.”
According to TipRanks.com, White is a 5-star analyst with an average return of 17.3% and a 49.7% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Aeglea Biotherapeutics Inc, and Spectrum Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for G1 Therapeutics Inc with a $63.50 average price target.
See today’s analyst top recommended stocks >>
Based on G1 Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $23.95 million. In comparison, last year the company had a GAAP net loss of $20.41 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
